UNAUDITED PRO FORMA CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION | |||||||||||||||||||||||||||||
As of September 30, 2022 (in billions) | As Reported | GE HealthCare Separation (a) | GE HealthCare Debt Issuance (b) | Transaction Accounting Adjustments | Proforma | ||||||||||||||||||||||||
Cash, cash equivalents and restricted cash | $ | 12.6 | $ | (0.5) | $ | 10.2 | $ | (8.2) | (c) | $ | 14.1 | ||||||||||||||||||
Investment securities | 6.3 | — | — | 5.1 | (d) | 11.4 | |||||||||||||||||||||||
Current receivables | 17.2 | (3.1) | — | 0.2 | (e) | 14.3 | |||||||||||||||||||||||
Inventories, including deferred inventory costs | 17.5 | (2.5) | — | — | 15.0 | ||||||||||||||||||||||||
Current contract assets | 3.7 | (0.6) | — | — | 3.1 | ||||||||||||||||||||||||
All other current assets | 2.8 | (0.4) | — | 0.3 | (e) | 2.6 | |||||||||||||||||||||||
Current assets | 60.1 | (7.2) | 10.2 | (2.7) | 60.4 | ||||||||||||||||||||||||
Investment securities | 33.6 | — | — | — | 33.6 | ||||||||||||||||||||||||
Property, plant and equipment – net | 14.3 | (2.1) | — | — | 12.2 | ||||||||||||||||||||||||
Goodwill | 25.3 | (12.8) | — | — | 12.5 | ||||||||||||||||||||||||
Other intangible assets – net | 7.7 | (1.6) | — | — | 6.1 | ||||||||||||||||||||||||
Contract and other deferred assets | 6.2 | (0.2) | — | — | 6.0 | ||||||||||||||||||||||||
All other assets | 22.2 | (0.9) | — | (0.7) | (f) | 20.5 | |||||||||||||||||||||||
Deferred income taxes | 11.5 | (0.5) | — | (2.0) | (f)(g)(h) | 9.0 | |||||||||||||||||||||||
Total assets | $ | 180.9 | $ | (25.2) | $ | 10.2 | $ | (5.5) | $ | 160.4 | |||||||||||||||||||
Short-term borrowings | $ | 4.3 | $ | — | $ | — | $ | — | $ | 4.3 | |||||||||||||||||||
Accounts payable and equipment project accruals | 17.3 | (3.0) | — | 0.1 | (e) | 14.4 | |||||||||||||||||||||||
Progress collections and deferred income | 16.4 | (1.8) | — | — | 14.7 | ||||||||||||||||||||||||
All other current liabilities | 16.6 | (1.7) | — | (0.1) | (e)(f)(g)(h)(i)(j) | 14.8 | |||||||||||||||||||||||
Current liabilities | 54.7 | (6.6) | — | — | 48.1 | ||||||||||||||||||||||||
Deferred income | 1.8 | (0.5) | — | — | 1.3 | ||||||||||||||||||||||||
Long-term borrowings | 26.1 | (0.1) | 10.2 | (16.6) | (k) | 19.6 | |||||||||||||||||||||||
Insurance liabilities and annuity benefits | 33.4 | — | — | — | 33.4 | ||||||||||||||||||||||||
Non-current compensation and benefits | 19.2 | (0.6) | — | (6.2) | (f)(h) | 12.4 | |||||||||||||||||||||||
All other liabilities | 12.9 | (1.1) | — | (0.1) | (c) | 11.7 | |||||||||||||||||||||||
Total liabilities | 148.1 | (8.8) | 10.2 | (23.0) | 126.5 | ||||||||||||||||||||||||
Preferred stock | — | — | — | — | — | ||||||||||||||||||||||||
Common stock | — | — | — | — | — | ||||||||||||||||||||||||
Accumulated other comprehensive income (loss) – net attributable to GE | (4.4) | 1.6 | — | (0.2) | (f)(h)(l) | (3.1) | |||||||||||||||||||||||
Other capital | 34.3 | 0.2 | — | — | 34.5 | ||||||||||||||||||||||||
Retained earnings | 82.7 | (18.2) | — | 17.7 | (m) | 82.2 | |||||||||||||||||||||||
Less common stock held in treasury | (81.0) | — | — | — | (81.0) | ||||||||||||||||||||||||
Total GE shareholders’ equity | 31.5 | (16.4) | — | 17.5 | 32.6 | ||||||||||||||||||||||||
Noncontrolling interests | 1.3 | — | — | — | 1.3 | ||||||||||||||||||||||||
Total equity | 32.8 | (16.4) | — | 17.5 | 33.9 | ||||||||||||||||||||||||
Total liabilities and equity | $ | 180.9 | $ | (25.2) | $ | 10.2 | $ | (5.5) | $ | 160.4 | |||||||||||||||||||
UNAUDITED PRO FORMA CONDENSED CONSOLIDATED STATEMENT OF EARNINGS (LOSS) | |||||||||||||||||||||||
For the nine months ended September 30, 2022 (In billions; per-share amounts in dollars) | As Reported | GE HealthCare Separation (n) | Transaction Accounting Adjustments | Proforma | |||||||||||||||||||
Revenues | |||||||||||||||||||||||
Sales of equipment | $ | 22.5 | $ | (6.9) | $ | — | $ | 15.6 | |||||||||||||||
Sales of services | 30.0 | (6.5) | — | 23.5 | |||||||||||||||||||
Insurance revenues | 2.2 | — | — | 2.2 | |||||||||||||||||||
Total revenues | 54.8 | (13.5) | — | 41.3 | |||||||||||||||||||
Costs and expenses | |||||||||||||||||||||||
Cost of equipment sold | 22.0 | (4.8) | — | 17.2 | |||||||||||||||||||
Cost of services sold | 18.1 | (3.4) | — | 14.7 | |||||||||||||||||||
Selling, general and administrative expenses | 9.2 | (2.6) | (0.1) | (o) | 6.5 | ||||||||||||||||||
Separation costs | 0.6 | — | (0.1) | (p) | 0.4 | ||||||||||||||||||
Research and development | 2.0 | (0.8) | — | 1.3 | |||||||||||||||||||
Interest and other financial charges | 1.2 | (0.1) | (0.3) | (q) | 0.8 | ||||||||||||||||||
Debt extinguishment costs | — | — | — | — | |||||||||||||||||||
Insurance losses, annuity benefits and other costs | 2.0 | — | — | 2.0 | |||||||||||||||||||
Goodwill impairments | — | — | — | — | |||||||||||||||||||
Non-operating benefit costs | (0.4) | — | 0.1 | (r) | (0.3) | ||||||||||||||||||
Total costs and expenses | 54.7 | (11.7) | (0.4) | 42.5 | |||||||||||||||||||
Other income | (0.9) | (0.1) | — | (1.0) | |||||||||||||||||||
Earnings (loss) from continuing operations before income taxes | (0.8) | (1.9) | 0.5 | (2.2) | |||||||||||||||||||
Benefit (provision) for income taxes | (0.5) | 0.4 | (0.1) | (w) | (0.2) | ||||||||||||||||||
Earnings (loss) from continuing operations | (1.4) | (1.5) | 0.4 | (2.5) | |||||||||||||||||||
Less net earnings (loss) attributable to noncontrolling interests | 0.1 | — | — | — | |||||||||||||||||||
Preferred stock dividends | (0.2) | — | — | (0.2) | |||||||||||||||||||
Net earnings (loss) from continuing operations attributable to GE common shareowners | $ | (1.6) | $ | (1.5) | $ | 0.4 | $ | (2.7) | |||||||||||||||
Per-share amounts | |||||||||||||||||||||||
Earnings (loss) from continuing operations | |||||||||||||||||||||||
Diluted earnings (loss) per share | $ | (1.46) | $ | (2.44) | |||||||||||||||||||
Basic earnings (loss) per share | $ | (1.46) | $ | (2.44) | |||||||||||||||||||
Average equivalent shares (in millions) | |||||||||||||||||||||||
Diluted | 1,097 | 1,097 | |||||||||||||||||||||
Basic | 1,097 | 1,097 |
UNAUDITED PRO FORMA CONDENSED CONSOLIDATED STATEMENT OF EARNINGS (LOSS) | |||||||||||||||||||||||
For the year ended December 31, 2021 (In billions; per-share amounts in dollars) | As Reported | GE HealthCare Separation (n) | Transaction Accounting Adjustments | Proforma | |||||||||||||||||||
Revenues | |||||||||||||||||||||||
Sales of equipment | $ | 34.2 | $ | (9.1) | $ | — | $ | 25.1 | |||||||||||||||
Sales of services | 36.9 | (8.6) | — | 28.3 | |||||||||||||||||||
Insurance revenues | 3.1 | — | — | 3.1 | |||||||||||||||||||
Total revenues | 74.2 | (17.7) | — | 56.5 | |||||||||||||||||||
Costs and expenses | |||||||||||||||||||||||
Cost of equipment sold | 31.4 | (6.2) | — | 25.2 | |||||||||||||||||||
Cost of services sold | 22.5 | (4.3) | — | 18.2 | |||||||||||||||||||
Selling, general and administrative expenses | 11.7 | (3.5) | (0.1) | (s) | 8.1 | ||||||||||||||||||
Separation costs | — | — | — | — | |||||||||||||||||||
Research and development | 2.5 | (0.8) | — | 1.7 | |||||||||||||||||||
Interest and other financial charges | 1.9 | (0.1) | (0.4) | (q) | 1.4 | ||||||||||||||||||
Debt extinguishment costs | 6.5 | — | 0.5 | (t) | 7.0 | ||||||||||||||||||
Insurance losses, annuity benefits and other costs | 2.4 | — | — | 2.4 | |||||||||||||||||||
Goodwill impairments | — | — | — | — | |||||||||||||||||||
Non-operating benefit costs | 1.8 | — | (0.6) | (r) | 1.1 | ||||||||||||||||||
Total costs and expenses | 80.7 | (15.0) | (0.6) | 65.1 | |||||||||||||||||||
Other income | 2.8 | (0.1) | — | 2.7 | |||||||||||||||||||
Earnings (loss) from continuing operations before income taxes | (3.7) | (2.9) | 0.6 | (5.9) | |||||||||||||||||||
Benefit (provision) for income taxes | 0.3 | 0.6 | (0.1) | (w) | 0.8 | ||||||||||||||||||
Earnings (loss) from continuing operations | (3.4) | (2.3) | 0.6 | (5.1) | |||||||||||||||||||
Less net earnings (loss) attributable to noncontrolling interests | (0.1) | — | — | (0.1) | |||||||||||||||||||
Preferred stock dividends | (0.2) | — | — | (0.2) | |||||||||||||||||||
Net earnings (loss) from continuing operations attributable to GE common shareowners | $ | (3.6) | $ | (2.3) | $ | 0.6 | $ | (5.3) | |||||||||||||||
Per-share amounts | |||||||||||||||||||||||
Earnings (loss) from continuing operations | |||||||||||||||||||||||
Diluted earnings (loss) per share | $ | (3.25) | $ | (4.80) | |||||||||||||||||||
Basic earnings (loss) per share | $ | (3.25) | $ | (4.80) | |||||||||||||||||||
Average equivalent shares (in millions) | |||||||||||||||||||||||
Diluted | 1,098 | 1,098 | |||||||||||||||||||||
Basic | 1,098 | 1,098 |
UNAUDITED PRO FORMA CONDENSED CONSOLIDATED STATEMENT OF EARNINGS (LOSS) | |||||||||||||||||||||||
For the year ended December 31, 2020 (In billions; per-share amounts in dollars) | As Reported | GE HealthCare Separation (n) | Transaction Accounting Adjustments | Proforma | |||||||||||||||||||
Revenues | |||||||||||||||||||||||
Sales of equipment | $ | 37.6 | $ | (10.0) | $ | — | $ | 27.6 | |||||||||||||||
Sales of services | 35.4 | (8.0) | 0.2 | (v) | 27.6 | ||||||||||||||||||
Insurance revenues | 2.9 | — | — | 2.9 | |||||||||||||||||||
Total revenues | 75.8 | (18.0) | 0.2 | 58.0 | |||||||||||||||||||
Costs and expenses | |||||||||||||||||||||||
Cost of equipment sold | 35.2 | (6.6) | — | 28.7 | |||||||||||||||||||
Cost of services sold | 22.6 | (4.1) | 0.2 | (v) | 18.7 | ||||||||||||||||||
Selling, general and administrative expenses | 12.6 | (3.4) | — | 9.2 | |||||||||||||||||||
Separation costs | — | — | — | — | |||||||||||||||||||
Research and development | 2.6 | (0.8) | — | 1.7 | |||||||||||||||||||
Interest and other financial charges | 2.1 | (0.1) | — | 2.0 | |||||||||||||||||||
Debt extinguishment costs | 0.3 | — | — | 0.3 | |||||||||||||||||||
Insurance losses and annuity benefits | 2.5 | — | — | 2.5 | |||||||||||||||||||
Goodwill impairments | 0.9 | — | — | 0.9 | |||||||||||||||||||
Non-operating benefit costs | 2.4 | — | (0.8) | (r) | 1.6 | ||||||||||||||||||
Total costs and expenses | 81.3 | (15.1) | (0.6) | 65.6 | |||||||||||||||||||
Other income | 11.4 | — | (12.3) | (u)(v) | (0.9) | ||||||||||||||||||
Earnings (loss) from continuing operations before income taxes | 6.0 | (3.0) | (11.5) | (8.5) | |||||||||||||||||||
Benefit (provision) for income taxes | 0.5 | 0.6 | 1.0 | (w) | 2.2 | ||||||||||||||||||
Earnings (loss) from continuing operations | 6.5 | (2.3) | (10.4) | (6.3) | |||||||||||||||||||
Less net earnings (loss) attributable to noncontrolling interests | (0.2) | (0.1) | — | (0.2) | |||||||||||||||||||
Preferred stock dividends | (0.5) | — | — | (0.5) | |||||||||||||||||||
Net earnings (loss) from continuing operations attributable to GE common shareowners | $ | 6.1 | $ | (2.3) | $ | (10.4) | $ | (6.6) | |||||||||||||||
Per-share amounts | |||||||||||||||||||||||
Earnings (loss) from continuing operations | |||||||||||||||||||||||
Diluted earnings (loss) per share | $ | 5.46 | $ | (6.16) | |||||||||||||||||||
Basic earnings (loss) per share | $ | 5.46 | $ | (6.16) | |||||||||||||||||||
Average equivalent shares (in millions) | |||||||||||||||||||||||
Diluted | 1,095 | 1,094 | |||||||||||||||||||||
Basic | 1,094 | 1,094 |
UNAUDITED PRO FORMA CONDENSED CONSOLIDATED STATEMENT OF EARNINGS (LOSS) | |||||||||||||||||||||||
For the year ended December 31, 2019 (In billions; per-share amounts in dollars) | As Reported | GE HealthCare Separation (n) | Transaction Accounting Adjustments | Proforma | |||||||||||||||||||
Revenues | |||||||||||||||||||||||
Sales of equipment | $ | 42.8 | $ | (11.6) | $ | — | $ | 31.2 | |||||||||||||||
Sales of services | 44.6 | (8.4) | 0.3 | (v) | 36.5 | ||||||||||||||||||
Insurance revenues | 2.8 | — | — | 2.8 | |||||||||||||||||||
Total revenues | 90.2 | (19.9) | 0.3 | 70.5 | |||||||||||||||||||
Costs and expenses | |||||||||||||||||||||||
Cost of equipment sold | 37.6 | (6.9) | — | 30.6 | |||||||||||||||||||
Cost of services sold | 27.3 | (4.4) | 0.3 | (v) | 23.2 | ||||||||||||||||||
Selling, general and administrative expenses | 13.8 | (4.0) | (0.1) | (o) | 9.7 | ||||||||||||||||||
Separation costs | — | — | — | — | |||||||||||||||||||
Research and development | 3.1 | (1.0) | — | 2.1 | |||||||||||||||||||
Interest and other financial charges | 2.9 | (0.2) | 0.1 | (v) | 2.8 | ||||||||||||||||||
Debt extinguishment costs | 0.3 | — | — | 0.3 | |||||||||||||||||||
Insurance losses and annuity benefits | 3.4 | — | — | 3.4 | |||||||||||||||||||
Goodwill impairments | 1.5 | — | — | 1.5 | |||||||||||||||||||
Non-operating benefit costs | 2.8 | — | (1.0) | (r) | 1.9 | ||||||||||||||||||
Total costs and expenses | 92.7 | (16.5) | (0.7) | 75.5 | |||||||||||||||||||
Other income | 2.4 | (0.1) | 0.1 | (v) | 2.4 | ||||||||||||||||||
Earnings (loss) from continuing operations before income taxes | (0.1) | (3.6) | 1.0 | (2.6) | |||||||||||||||||||
Benefit (provision) for income taxes | (0.6) | 0.7 | 0.5 | (w) | 0.7 | ||||||||||||||||||
Earnings (loss) from continuing operations | (0.6) | (2.9) | 1.6 | (1.9) | |||||||||||||||||||
Less net earnings (loss) attributable to noncontrolling interests | — | — | — | — | |||||||||||||||||||
Preferred stock dividends | (0.5) | — | — | (0.5) | |||||||||||||||||||
Net earnings (loss) from continuing operations attributable to GE common shareowners | $ | (1.1) | $ | (2.8) | $ | 1.6 | $ | (2.3) | |||||||||||||||
Per-share amounts | |||||||||||||||||||||||
Earnings (loss) from continuing operations | |||||||||||||||||||||||
Diluted earnings (loss) per share | $ | (0.98) | $ | (2.14) | |||||||||||||||||||
Basic earnings (loss) per share | $ | (0.98) | $ | (2.14) | |||||||||||||||||||
Average equivalent shares (in millions) | |||||||||||||||||||||||
Diluted | 1,091 | 1,091 | |||||||||||||||||||||
Basic | 1,091 | 1,091 |
(a) | Adjustments represent the elimination of assets and liabilities attributable to GE HealthCare. | |||||||||||||||||||
(b) | Adjustment represents $10.2 billion of cash received by GE, in connection with the Separation, funded by GE HealthCare's long-term debt issuance. | |||||||||||||||||||
(c) | Adjustment represents cash used for repayment of GE debt of $6.9 billion ($6.4 billion principal payment and $0.5 billion debt extinguishment cost) plus cash proceeds retained by GE HealthCare of $1.3 billion, which included a term loan of $2.0 billion, partially offset by a cash distribution to GE of $0.7 billion. All other liabilities was reduced by $0.1 billion for the tax impact of the debt extinguishment costs. | |||||||||||||||||||
(d) | Adjustment represents approximately 90.3 million shares or 19.9% ownership interest in GE HealthCare retained by GE at an opening price per share of $56.00 on January 4, 2023, totaling $5.1 billion. | |||||||||||||||||||
(e) | Balance sheet adjustments primarily relating to reversal of intercompany eliminations for shared services and hedging arrangements between GE and GE HealthCare as follows: | |||||||||||||||||||
($ in billions) | As of Sept. 30, 2022 | |||||||||||||||||||
Current receivables | $ | 0.2 | ||||||||||||||||||
All other current assets | $ | 0.3 | ||||||||||||||||||
Accounts payable and equipment project accruals | $ | 0.2 | ||||||||||||||||||
All other current liabilities | $ | 0.3 | ||||||||||||||||||
(f) | In connection with the Separation, a portion of GE’s principal pension plans, which consists of the GE Pension Plan and GE Supplementary Pension Plan, the GE Principal Retiree Benefit Plans and Other Pension Plans including U.S. and non-U.S. pension plans were transferred to GE HealthCare. The pro forma adjustments reflect plan assets and obligations primarily associated with GE HealthCare’s active, retired, and other former GE employees in certain jurisdictions. The adjustments in the unaudited pro forma condensed combined statement of financial position as of September 30, 2022 are as follows: | |||||||||||||||||||
($ in billions) | As of Sept. 30, 2022 | |||||||||||||||||||
All other assets | $ | (0.7) | ||||||||||||||||||
Deferred income taxes | $ | (1.2) | ||||||||||||||||||
All other current liabilities | $ | (0.3) | ||||||||||||||||||
Non-current compensation and benefits | $ | (5.6) | ||||||||||||||||||
Accumulated other comprehensive income (loss) – net | $ | (1.2) | ||||||||||||||||||
(g) | Adjustments reflect the transfer of deferred tax assets of $0.7 billion to GE HealthCare and a reduction of current tax liabilities of $0.2 billion. | |||||||||||||||||||
(h) | In connection with the Separation, current compensation and benefits obligations with respect to additional employee-related obligations of active, retired, and other former employees along with non-current benefits obligations pertaining to deferred compensation arrangements and severance liabilities were transferred from GE to GE HealthCare. The adjustments in the unaudited pro forma condensed combined statement of financial position as of September 30, 2022 are as follows: | |||||||||||||||||||
($ in billions) | As of Sept. 30, 2022 | |||||||||||||||||||
Deferred income taxes | $ | (0.2) | ||||||||||||||||||
All other current liabilities | $ | (0.2) | ||||||||||||||||||
Non-current compensation and benefits | $ | (0.6) | ||||||||||||||||||
Accumulated other comprehensive income (loss) – net | $ | (0.1) | ||||||||||||||||||
(i) | Subsequent to the Separation, GE anticipates it will incur additional one-time costs of approximately $0.1 billion for the development of technological infrastructure on behalf of GE HealthCare. These costs are expected to be incurred within one year of the Separation and have been reflected as an adjustment to retained earnings. | |||||||||||||||||||
(j) | Adjustment reflects additional tax liabilities of $0.3 billion recorded by GE as a result of the Separation. | |||||||||||||||||||
(k) | Adjustment reflects GE debt repayment of $6.4 billion and the removal of GE HealthCare's long-term debt of $10.2 billion as a result of the Separation. |
(l) | Adjustment includes currency translation loss of $1.1 billion attributable to the GE HealthCare business transferred to retained earnings. | |||||||||||||||||||
(m) | Represents the effect of adjustments described in notes (c) through (l) on stockholders' equity. | |||||||||||||||||||
(n) | Adjustments reflect the elimination of revenues and costs and expenses of GE HealthCare. | |||||||||||||||||||
(o) | Adjustment primarily reflects restructuring costs incurred by GE on behalf of GE HealthCare. | |||||||||||||||||||
(p) | Adjustment reflects separation costs incurred by GE that were directly attributable to GE HealthCare. | |||||||||||||||||||
(q) | Adjustment reflects the reduction of interest expense of $0.3 billion and $0.4 billion to give effect to the estimated repayment of debt for the nine months ended September 30, 2022 and the year ended December 31, 2021, respectively. | |||||||||||||||||||
(r) | Adjustment reflects non-operating costs for pension and retirement benefit plans and costs for employee related obligations transferred to GE HealthCare in connection with the Separation. | |||||||||||||||||||
(s) | Adjustment primarily reflects the impact of the transition services agreement whereby GE and GE HealthCare will provide certain post separation services on a transitional basis which results in a reduction in sales, general and administrative expenses not included in GE’s historical financial statements. | |||||||||||||||||||
(t) | Adjustment reflects debt extinguishments costs incurred by GE in connection with GE's debt repayment as a result of the Separation. | |||||||||||||||||||
(u) | Adjustment reflects the pre-tax gain on the sale of $12.4 billion related to GE HealthCare’s BioPharma business in March of 2020. | |||||||||||||||||||
(v) | Income statement adjustments to reverse intercompany eliminations, primarily related to services provided from GE HealthCare to GE and vice versa, are as follows: | |||||||||||||||||||
($ in billions) | Year ended Dec. 31, 2020 | Year ended Dec. 31, 2019 | ||||||||||||||||||
Sales of services | $ | 0.2 | $ | 0.3 | ||||||||||||||||
Cost of services sold | $ | 0.2 | $ | 0.3 | ||||||||||||||||
Interest and other financial charges | $ | — | $ | 0.1 | ||||||||||||||||
Other income | $ | 0.1 | $ | 0.1 | ||||||||||||||||
(w) | Adjustment reflects the estimated income tax impact of the pro forma transaction accounting adjustments at the applicable statutory income tax rates in effect within the respective tax jurisdictions during the periods presented. |